Circulating tumour cell isolation, analysis and clinical application

Zhang, Xiaoli; Xie, PeiPei; Zhang, KaiTai; Zhang, Wen

doi:10.1007/s13402-023-00774-0

Cited by 5 publications

(2 citation statements)

References 68 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Various bioassay techniques, including NP platforms with antibody conjugation and immunomagnetic beads (IMBs), have been developed to precisely detect and selectively isolate CTCs from the peripheral blood of cancer patients. [68,69] For instance, the CellSearch system, approved by the U.S. Food and Drug Administration, employs IMBs for the collection and enrichment of CTCs. [70] However, the CTC recovery rate and the purity of these systems have been constrained by the nonspecific adsorption of WBCs onto the IMBs.…”

Section: Hybrid Cnps For Disease Diagnosismentioning

confidence: 99%

Hybrid Cell Membrane‐Coated Nanoparticles for Biomedical Applications

Yu,

Peng,

Shen

et al. 2024

Small Structures

View full text Add to dashboard Cite

There is growing interest in developing cell membrane‐coated nanoparticles (CNPs) for unique host cell mimicry and therapeutic applications. The continuous evolution of this technology has motivated the coating of nanoparticles with hybrid membranes originating from diverse cell types. The resulting hybrid cell membrane‐coated nanoparticles (hybrid CNPs) exhibit a higher level of synergy among multifunctionalities with better multitasking capabilities than their monotypic membrane‐coated counterparts. This advancement has catalyzed the initiation of numerous research opportunities, marking the advent of a promising frontier in therapeutic applications. This review outlines emerging biomedical applications of hybrid CNPs, focusing on drug targeting, immune modulation, biological neutralization, and disease diagnosis. Within each application, the review underscores how the strategic hybridization of distinct cell membranes augments the resulting nanoparticle therapeutic efficacy. Overall, the insights presented herein consolidate our understanding of current applications and may inspire novel designs with new biomedical applications.

show abstract

Section: Hybrid Cnps For Disease Diagnosismentioning

confidence: 99%

Hybrid Cell Membrane‐Coated Nanoparticles for Biomedical Applications

Yu,

Peng,

Shen

et al. 2024

Small Structures

View full text Add to dashboard Cite

show abstract

“…Firstly, this method may overlook CTCs that poorly express or have a lack of epithelial surface markers ( 16 ). Secondly, CellSearch ® is also unable to interstitially identify tumors that express little or no EpCAM of mesenchymal origin, as well as epithelial-derived CTCs that are partially in EMT; several published reports have highlighted this issue ( 11 , 17 - 21 ), which severely limits the clinical application of CellSearch ® . In this study, we constructed a novel multiplexed magnetic bead enrichment platform in which we used EpCAM-coated immunoliposomal magnetic beads (Ep-IMBs) and vimentin-coated immunoliposomal magnetic beads (Vi-IMBs) sequentially to capture CTCs.…”

Section: Introductionmentioning

confidence: 99%

Prognostic evaluation of a multi-target magnetic bead-enriched circulating tumor cell-enriched identification system for colorectal cancer

Wang,

Xia,

et al. 2024

J Gastrointest Oncol

View full text Add to dashboard Cite

Background Colorectal cancer (CRC) is the third most prevalent cancer in the world. Traditional tissue biopsy cannot provide dynamic monitoring of patients’ tumors or reflect the characteristics of tumors in real time because the sampling process is invasive and accompanied by risks. Circulating tumor cells (CTCs) are considered a major cause of tumor metastasis, and investigating CTCs helps to understand the biology and vulnerability of malignant tumors during hematogenous metastasis. Methods We sequentially used epithelial cell adhesion molecule (EpCAM)-coated immunoliposomal magnetic beads (Ep-IMBs) and vimentin-coated immunoliposomal magnetic beads (Vi-IMBs) to capture and characterize CTCs from 110 CRC patients. We further constructed a Cox risk regression model, optimized the model composition using backward stepwise regression, and finally applied nomograms to show the effect of each variable on survival risk. Results The specificity of the CTCs enrichment and identification system was 100% and the sensitivity was 79.0%. Multivariate analysis indicated total CTC number was an important predictor for bad survival, whereas American Joint Committee on Cancer (AJCC) stage, lymph node metastasis, and carcinoembryonic antigen (CEA) level were associated with prognosis, and the risk of mortality was associated with the AJCC stage of the CRC. Conclusions The CTC enrichment and identification system constructed in this research demonstrated superior accuracy. In addition, CTCs can be used as an important predictor for prognosis of patients with CRC, and the combination of other clinical predictive factors can help clinicians to better design individualized treatment regimens, which is of great clinical application value.

show abstract

Precision treatment in advanced hepatocellular carcinoma

Yang,

Zhang

et al. 2024

Cancer Cell

View full text Add to dashboard Cite

Circulating tumour cell isolation, analysis and clinical application

Cited by 5 publications

References 68 publications

Hybrid Cell Membrane‐Coated Nanoparticles for Biomedical Applications

Hybrid Cell Membrane‐Coated Nanoparticles for Biomedical Applications

Prognostic evaluation of a multi-target magnetic bead-enriched circulating tumor cell-enriched identification system for colorectal cancer

Precision treatment in advanced hepatocellular carcinoma

Contact Info

Product

Resources

About